Imfinzi®

Understanding IMFINZI®

IMFINZI® (durvalumab) is a monoclonal antibody that helps the immune system fight cancer by blocking PD-L1 (programmed death-ligand 1), a protein that tumors use to evade immune detection. It is used to treat certain types of cancer, including non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), and biliary tract cancer (BTC).

How IMFINZI® Works:

• Targets and blocks PD-L1, restoring the immune system’s ability to detect and destroy cancer cells.
• Enhances T-cell activation, allowing the body’s natural defenses to attack tumors more effectively.
• Reduces tumor growth and spread in eligible patients with advanced or unresectable cancers.
• Can be used alone or in combination with chemotherapy or other immunotherapies for enhanced effectiveness.

FDA Approval:

• 2017 – Approved for Stage III Non-Small Cell Lung Cancer (NSCLC) after chemoradiotherapy.
• 2018 – Approved for Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in combination with chemotherapy.
• 2022 – Approved for Biliary Tract Cancer (BTC) in combination with chemotherapy.

For more information, please visit the Imfinzi® patient website and speak with your healthcare provider to determine if Imfinzi® is the right treatment option for you.